The bootstrapped San Francisco eClinical company that has been quietly running thousands of clinical trials while everyone else was busy renaming themselves.
She is in Lyon. The study she is running enrolls patients in twelve countries. The protocol changed eleven days ago. Yesterday a monitor flagged seventeen queries. None of this is unusual. What would have been unusual, twenty years ago, is that she handles the whole thing in a browser - one platform, one login, one audit trail. The company underneath that browser tab, more often than you would guess, is Medrio.
Medrio does not advertise on the side of stadiums. It does not stage keynotes about reinventing the patient. It writes software for a job that most of the world will never think about, and it has been writing it since 2005.
For decades, the way pharmaceutical companies collected data from clinical studies looked like a war crime against trees. Paper case report forms travelled by courier from sites in Brno or Bangalore back to a coordinating center, where someone with a steady hand and a magnifying glass keyed them into a database. Errors were inevitable. Audit trails were optional. Mid-study changes were the stuff of weekend panic.
When the first wave of electronic data capture vendors arrived in the early 2000s, they mostly recreated the same pain inside a desktop application. Enterprise software for studies that, more often than not, ran on a shoestring budget at small biotechs and medtech startups. A simple Phase I trial could spend six figures and four months just to get the database up.
This was, depending on your perspective, either an unfortunate state of affairs or an enormous business opportunity. Medrio took the second view.
It was 2005. The cool kids were building consumer-facing web 2.0 startups with lowercase names and rounded corners. Mike Novotny was in a San Francisco apartment writing an electronic data capture system that a non-programmer could configure in an afternoon. He bet on three things at once - and all three turned out to matter.
Browser-delivered software for an industry that still trusted floppy disks. Awkward at the time. Obvious in hindsight.
A study build interface a clinical project manager could operate without filing a ticket. Permanent threat to consulting hours.
Small biotechs and medical-device shops that big EDC vendors did not bother returning calls to.
For roughly twelve years Medrio took no outside money. It grew the way unfashionable companies grow - one customer, one renewal, one referral at a time. By 2017, when Questa Capital led a $30 million round, Medrio was already profitable and already global. The capital was for acceleration, not survival. Which is, in venture economics, the polite version of a flex.
Milestones from a company that has resisted, on principle, the urge to celebrate them.
Medrio's pitch is straightforward enough that you can put it on a single slide and only the lawyer at the back will complain. The platform handles the unglamorous infrastructure of running a clinical trial - capturing data, asking patients how they feel, getting their consent, and making sure the right pill gets to the right person at the right site.
The original. Cloud-based electronic data capture with a no-code study builder. Mid-study changes. Offline entry. Audit trails that survive auditors.
Patient-reported outcomes on the participant's own phone. Translations. Reminders. The unsexy work of compliance.
Informed consent for in-clinic, hybrid and fully decentralized studies. Signatures that hold up to regulators.
Randomization and trial supply management, integrated. Drug at the site, not in customs.
Project managers, data managers and biostatisticians from Medrio's own bench, billed by the hour and worth it.
Released January 2025. Ask the database a question, get an answer that did not require a SQL whisperer.
Software for clinical trials does not get reviewed on Product Hunt. The proof is in the studies that finish and the regulators that nod. By that scoreboard, Medrio is doing well.
Medrio's mission, stripped of marketing varnish, is that the bottleneck in getting a new therapy to a patient should not be the database. It should be the biology. The platform exists to push as much of the operational drag - the spreadsheets, the file transfers, the integration tickets - out of the way of the people who are actually trying to figure out whether a molecule works.
This sounds modest. It is not. Roughly half the cost of a clinical trial is data management and site operations. Shaving weeks off a study build, or removing a hand-off between two vendors, compounds across thousands of trials into real human time. Possibly into real human lives. Medrio is reluctant to phrase it that way out loud. We will phrase it that way for them.
The shape of clinical research is changing. Patients want to participate from home. Sponsors want to run adaptive protocols that change mid-study. Regulators want more data, in more places, with more provenance. The old assumption - that a trial is a thing that happens inside a hospital, on paper, supervised by one site coordinator - is collapsing on every axis at once.
Decentralized and hybrid trials need software that does not assume a wired ethernet jack. They need consent that travels. They need randomization that respects time zones. They need data capture that works offline in a village clinic and syncs cleanly when a signal returns. They need, in other words, exactly what Medrio has been building, on purpose, for two decades.
Add AI-enabled reporting on top, and the next five years of clinical research start to look like the kind of thing a single coordinator in Lyon can run without losing a weekend. Which, conveniently, is where this story began.
The coordinator closes seventeen queries. Approves the protocol amendment. Triggers a randomization. Glances at an AI-generated study summary that, two years ago, would have required a phone call to a biostatistician in another time zone. She gets coffee.
None of this looks like progress, which is the highest compliment software in this category can earn. Medrio's job, the one it has been doing since 2005, is to be the part of the trial that you do not have to think about. On a good morning - and there are increasingly more good mornings - you do not.
Sources: medrio.com, Crunchbase, MobiHealthNews, Questa Capital, Tracxn, The Healthcare Insights.